Compass Therapeutics, Inc.

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Read the news release at https://ow.ly/QijC50SXxmp

Compass CEO Thomas Schuetz, MD, PhD, will present at the 2024 Wedbush PacGrow Healthcare Conference on August 13-14 in New York City. This invitation-only event will feature executives of leading public and private companies in the healthcare sector.

We're thrilled to welcome Talia Fountain to the Compass Therapeutics team as our new Clinical Trial Associate!

New in Future Oncology journal: COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC
Read the full article at https://ow.ly/b0hK50S90M8

Join Compass Therapeutics CEO, Thomas Schuetz, MD, PhD, at the Jefferies Global Healthcare Conference 2024 for a Fireside Chat on June 5 at 1 p.m. ET.

➡️ In-person: Track 2 - Plymouth, 6th Floor

➡️ Online: Register for the webcast at https://bit.ly/3KkjpbF

At the 2024 ASCO Annual Meeting, we'll present data from the Phase 1 Study of our novel anti-CD137 antibody, CTX-471, and its safety and anti-tumor activity in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Clinical responses observed to date demonstrate the potential of our novel anti-CD137 antibody in patients with advanced refractory malignancies who have limited treatment options.

Read more: https://ow.ly/QE7550RTQi4

Join Vered Bisker-Leib, PhD, Compass Therapeutics CEO, in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, at 11:30 a.m. ET.
Register now for the live Webcast at https://ow.ly/hJRW50REL6Y

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
https://ow.ly/L8U050REmE2

COMPANION-002, our Biliary Tract Cancer clinical trial, was recently covered by CCA News. Read the full article at: https://ow.ly/om7a50RzK8u

COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC | CCA News Online A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.

ICYMI: Here's the Cholangiocarcinoma Foundation webinar with Dr. Thomas Schuetz, President of R&D, discussing the Investigational Drug CTX-009 and the Phase 2/3 Biliary Tract Cancer Clinical Trial.

Watch now on the CCF YouTube channel: https://ow.ly/3obr50Rytjm

Cancer

CCF Webinar: Investigational Drug CTX-009 & the COMPANION-002 Study of CTX-009 in patients with BTC Dr. Thomas Schuetz, President of R&D at Compass Therapeutics discusses the Investigational Drug CTX-009 and the Phase 2/3 Biliary Tract Cancer Clinical Trial...

We are at the Cholangiocarcinoma Foundation Annual Conference in Salt Lake City! We are honored to present our trial in progress and translational research posters.

This conference is a wonderful opportunity for patients, industry, and clinicians to come together in a collective effort to create hope and share research about biliary tract cancers.

To view our posters, see here: cmpx.info/posters

Join Vered Bisker-Leib, Compass Therapeutics CEO, as she presents at the Stifel 2024 Targeted Oncology Days on Tuesday, April 16, at 11 a.m. ET.

Register now for the live webcast and post-event replay at CMPX.info/stifel.

Tomorrow at the AACR Annual Meeting, four of Compass’s scientists will discuss an investigation into the therapeutic potential of the company’s lead programs, CTX-009 and CTX-471.

The findings suggest that when combined, CTX-009 and CTX-471 may provide a treatment option for patients in whom immune-oncology therapies have failed.

We’re proud to announce Feny Gunawan, a highly strategic CMC leader, has joined the Compass team as our CMC Director!

The women of Compass celebrate each other daily, but especially today on International Women’s Day!
We work together to advance research in cancer and accelerate our clinical programs to help patients.

Join Vered Bisker-Leib, PhD, MBA, Compass Therapeutics CEO, for a Fireside Chat at the Leerink Partners Global BioPharma Conference on Wednesday, March 13, starting at 10:40 a.m. ET. Register now for the live webcast at cmpx.info/Leerink.

We're proud to announce the publication of very promising pre-clinical data for our next generation PD-1/PD-L1 bispecific antibody, CTX-8371, in the journal OncoImmunology.

CTX-8371 outperformed approved checkpoint inhibitors in a series of in vitro and in vivo preclinical experiments. In addition, the data reveal synergistic activity of the combination of CTX-8371 and the Compass CD-137 agonist, CTX-471.

The preclinical data supported the acceptance of our US IND submission and we are excited to treat the first patients with CTX-8371 in Q1 2024.

Read our entire announcement at https://bit.ly/3TbhFqh.

Today is World Cholangiocarcinoma Awareness Day! Today our team wears . Learn more about the disease from the Cholangiocarcinoma Foundation: https://ow.ly/O2sB50QCcnR and our involvement: https://ow.ly/BzmK50QCcnQ

We're grateful for the opportunity to have joined American Society of Clinical Oncology community and connect with leading experts in at the ASCO 2024 Gastrointestinal Cancers Symposium.
To learn more about COMPANION-002, our ongoing clinical trial for patients with biliary tract cancer, please follow this link: https://ow.ly/uuTz50QuNin

Today, we congratulate Vered Bisker-Leib as she becomes the new Chief Executive Officer at Compass Therapeutics.
We also celebrate our CEO of 10 years and scientific co-founder, Thomas Schuetz, who will transition to President of R&D and Vice Chairman of the Board.
All of us at Compass look forward to the year ahead as we continue our mission to improve patients' lives with transformative cancer therapies.
https://ow.ly/LC7t50QoZ4j

"Compass Therapeutics Provides Corporate Update"
Read the news release at: https://ow.ly/RBoB50Qoj8y

Jim Palma, TargetCancer Foundation CEO; Minori Rosales, MD, PhD, Compass SVP and Head of Clinical Development; and Karin Herrera, VP and Head of Clinical Operations at the TargetCancer "Think Tank on Advancing Precision Medicine in Rare Cancers" in Boston.

We are pleased to announce that Natalie Warholic has joined our team as Director of Clinical Operations. Welcome, Natalie!
Learn more about Compass at https://ow.ly/uGcp50Q4LoM.

Vered Bisker-Leib, Ph.D., MBA, Compass President and COO, will present at the Jefferies London Healthcare Conference on Thursday, November 16, at 2:30 p.m. GMT. Register now to join by webcast: https://cmpx.info/jefferies

Thomas J. Schuetz, MD, Ph.D., Compass Co-Founder and CEO, will present at the Stifel Healthcare Conference on Tuesday, November 14, at 9:45 a.m. EST.
Register now to view the webcast: https://cmpx.info/stifel.

We are excited to introduce our newest team member, Kris Sachsenmeier, as Vice President and Head of Translational Research. Welcome, Kris!
Learn more about Compass at https://ow.ly/b2fx50Q4LpO.

It was a pleasure to discuss COMPANION-002, our Biliary Tract Cancer Clinical Trial, with a panel of experts like Dr. Milind Javle at the 5th Annual Cholangiocarcinoma Summit.

Cancer research begins with dedicated scientists who work every day to find treatments for patients. Here at Compass, we are proud of moving cancer research forward!

Join the Fireside Chat with Vered Bisker-Leib, Ph.D., MBA, Compass Therapeutics President and Chief Operating Officer, at the Cantor Fitzgerald Global Healthcare Conference in NYC on Wed. Sept. 27, from 2:25 p.m. to 2:55 p.m. ET.
Register now for the live Webcast at cmpx.info/cantor.

Join us as Thomas Schuetz, MD, Ph.D., Compass Therapeutics Co-Founder & CEO, presents to the H.C. Wainwright 25th Annual Global Investment Conference in NYC on Monday, September 11, at 4 p.m. ET.
Register now for the live Webcast at cmpx.info/hcw.